The change of macular thickness measured by optical coherence tomography in relation to glycemic control in diabetic patients

  • Sang Woong Moon
  • Hee-Young Kim
  • Seong-Woo Kim
  • Jaeryung Oh
  • Kuhl Huh
  • In Kyung Oh
Retinal Disorders



To demonstrate the change in macular thickness using optical coherence tomography in diabetic patients and to assess its relationship with glycosylated hemoglobin (HbA1c) levels.


Diabetic patients who underwent at least two macular thickness measurements with OCT within a 12-month period were included. HbA1c values within 1 month of each OCT study, and clinical data such as age, insulin treatment, systemic hypertension, and the severity of diabetic retinopathy were collected. The change in three macula parameters including center point thickness (CPT), central subfoveal macular thickness (CSMT), and total macular volume (TMV) between two measurements was calculated. Patients were divided into two groups based on the half-width of the 95% confidence interval for percent change, the increase group (group 1) and the decrease group (group 2). The associations of CPT change, CSMT change, and TMV change with baseline HbA1c levels, HbA1c change, and other clinical factors were investigated using correlation analysis and group comparison.


A total of 23 eyes of 23 patients were studied. In correlation analysis; the increase in CPT, CSMT, and TMV was correlated with baseline HbA1c (CPT, Spearman's rho = 0.462, p = 0.027; CSMT, Spearman's rho = 0.479, p = 0.021; TMV, Spearman's rho = 0.589, p = 0.003), and the change of HbA1c (CPT, Spearman's rho = −0.585, p = 0.003; CSMT, Spearman's rho = −0.583, p = 0.004; TMV, Spearman's rho = −0.725, p < 0.001). In group comparison for CPT, group 1 have a higher baseline HbA1c (11.2% vs 8.7% of THb, p = 0.044) and a greater HbA1c reduction (−3.3% vs −1.2% of THb, p = 0.044) than group 2. For CSMT, group 1 tended to have a greater HbA1c reduction (−2.9% vs −1.2% of THb, p = 0.074) than group 2. For TMV, group 1 had a higher baseline HbA1c (11.6% vs 8.4% of THb, p = 0.001) and a greater HbA1c reduction (−3.5% vs −0.5% of THb, p < 0.001) than group 2.


The change in macular thickness and volume developed in relation to HbA1c levels during a less than 12-month period. A high baseline HbA1c and a large reduction of HbA1c were risk factors for the increase in macular thickness. Prospective study with a large number of patients is needed to clarify the change of macular thickness in relation to glycemic control.


Diabetic macular edema Glycosylated hemoglobin Optical coherence tomography 


  1. 1.
    The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977–986CrossRefGoogle Scholar
  2. 2.
    UK prospective diabetes study (UKPDS) group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837–853CrossRefGoogle Scholar
  3. 3.
    Roysarkar TK, Gupta A, Dash RJ, Dogra MR (1993) Effect of insulin therapy on progression of retinopathy in noninsulin-dependent diabetes mellitus. Am J Ophthalmol 115:569–574PubMedGoogle Scholar
  4. 4.
    van Ballegooie E, Hooymans JM, Timmerman Z, Reitsma WD, Sluiter WJ, Schweitzer NM, Doorenbos H (1984) Rapid deterioration of diabetic retinopathy during treatment with continuous subcutaneous insulin infusion. Diab Care 7:236–242CrossRefGoogle Scholar
  5. 5.
    Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T (1985) Two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes 34(Suppl 3):74–79PubMedGoogle Scholar
  6. 6.
    Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O (1985) Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J (Clin Res Ed) 290:811–815CrossRefGoogle Scholar
  7. 7.
    Brinchmann-Hansen O, Dahl-Jorgensen K, Hanssen KF, Sandvik L (1988) The response of diabetic retinopathy to 41 months of multiple insulin injections, insulin pumps, and conventional insulin therapy. Arch Ophthalmol 106:1242–1246PubMedGoogle Scholar
  8. 8.
    Funatsu H, Yamashita H, Ohashi Y, Ishigaki T (1992) Effect of rapid glycemic control on progression of diabetic retinopathy. Jpn J Ophthalmol 36:356–367PubMedGoogle Scholar
  9. 9.
    Agardh CD, Eckert B, Agardh E (1992) Irreversible progression of severe retinopathy in young type I insulin-dependent diabetes mellitus patients after improved metabolic control. J Diab Complications 6:96–100CrossRefGoogle Scholar
  10. 10.
    Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD (2005) Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—the EURODIAB Prospective Complications Study. Diabetologia 48:370–378PubMedCrossRefGoogle Scholar
  11. 11.
    Henricsson M, Nilsson A, Janzon L, Groop L (1997) The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet Med 14:123–131PubMedCrossRefGoogle Scholar
  12. 12.
    The Diabetes Control and Complications Trial Research Group (1998) Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 116:874–886Google Scholar
  13. 13.
    Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V (2003) Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diab Care 26:1485–1489CrossRefGoogle Scholar
  14. 14.
    Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP, Emanuele NV, Levin SR, Pacold I, Lee HS (1997) Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 157:181–188PubMedCrossRefGoogle Scholar
  15. 15.
    Koppel BS, Daras M (1993) Transient hypodensity on CT scan during hypoglycemia. Eur Neurol 33:80–82PubMedCrossRefGoogle Scholar
  16. 16.
    Shirayama H, Ohshiro Y, Kinjo Y, Taira S, Teruya I, Nakachi K, Tawata M, Takasu N (2004) Acute brain injury in hypoglycaemia-induced hemiplegia. Diabet Med 21:623–624PubMedCrossRefGoogle Scholar
  17. 17.
    Wright RJ, Frier BM (2008) Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diab Metab Res Rev 24:353–363CrossRefGoogle Scholar
  18. 18.
    Early Treatment Diabetic Retinopathy Study Research Group (1991) Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 98:786–806Google Scholar
  19. 19.
    Collier A, Matthews DM, Young RJ, Clarke BF (1987) Transient atrial fibrillation precipitated by hypoglycaemia: two case reports. Postgrad Med J 63:895–897PubMedCrossRefGoogle Scholar
  20. 20.
    Malouf R, Brust JC (1985) Hypoglycemia: causes, neurological manifestations, and outcome. Ann Neurol 17:421–430PubMedCrossRefGoogle Scholar
  21. 21.
    Fisher BM, Quin JD, Rumley A, Lennie SE, Small M, MacCuish AC, Lowe GD (1991) Effects of acute insulin-induced hypoglycaemia on haemostasis, fibrinolysis and haemorheology in insulin-dependent diabetic patients and control subjects. Clin Sci (Lond) 80:525–531Google Scholar
  22. 22.
    Ibbotson SH, Catto A, Davies JA, Grant PJ (1995) The effect of insulin-induced hypoglycaemia on factor VIII:C concentrations and thrombin activity in subjects with type 1 (insulin-dependent) diabetes. Thromb Haemost 73:243–246PubMedGoogle Scholar
  23. 23.
    Galloway PJ, Thomson GA, Fisher BM, Semple CG (2000) Insulin-induced hypoglycemia induces a rise in C-reactive protein. Diab Care 23:861–862CrossRefGoogle Scholar
  24. 24.
    Jialal I, Devaraj S, Venugopal SK (2004) C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 44:6–11PubMedCrossRefGoogle Scholar
  25. 25.
    Wright RJ, Macleod KM, Perros P, Johnston N, Webb DJ, Frier BM (2007) Plasma endothelin response to acute hypoglycaemia in adults with Type 1 diabetes. Diabet Med 24:1039–1042PubMedCrossRefGoogle Scholar
  26. 26.
    Krzystolik MG, Strauber SF, Aiello LP, Beck RW, Berger BB, Bressler NM, Browning DJ, Chambers RB, Danis RP, Davis MD, Glassman AR, Gonzalez VH, Greenberg PB, Gross JG, Kim JE, Kollman C (2007) Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology 114:1520–1525PubMedCrossRefGoogle Scholar
  27. 27.
    Browning DJ, Fraser CM, Propst BW (2008) The variation in optical coherence tomography-measured macular thickness in diabetic eyes without clinical macular edema. Am J Ophthalmol 145:889–893PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Sang Woong Moon
    • 1
  • Hee-Young Kim
    • 2
  • Seong-Woo Kim
    • 3
  • Jaeryung Oh
    • 3
  • Kuhl Huh
    • 3
  • In Kyung Oh
    • 4
  1. 1.Department of OphthalmologyKyung Hee University College of MedicineSeoulSouth Korea
  2. 2.Department of BiostatisticsKorea UniversitySeoulSouth Korea
  3. 3.Department of OphthalmologyKorea University College of MedicineSeoulSouth Korea
  4. 4.Dr. Oh’s Eye ClinicUijeongbu-siSouth Korea

Personalised recommendations